Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective

Area of Science:

• Hepatology
• Metabolic Medicine
• Lipid Metabolism

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by hepatic lipid accumulation, strongly associated with metabolic syndrome and cardiovascular disease.
• Very low-density lipoprotein (VLDL) is crucial for triglyceride transport from the liver, and its dysregulation is implicated in MASLD pathogenesis.

Purpose of the Study:

• To review the intricate relationship between VLDL synthesis, metabolism, and the development of MASLD.
• To elucidate the crosstalk between MASLD and VLDL for novel therapeutic strategies.

Main Methods:

• Literature review focusing on VLDL structure, composition, biosynthesis, and metabolic pathways in MASLD.
• Analysis of how adipose-derived factors influence hepatic VLDL metabolism during MASLD progression.

Main Results:

• Excessive VLDL production and altered metabolism contribute to elevated blood triglycerides, promoting hepatic fat deposition characteristic of MASLD.
• Changes in VLDL structure and composition, alongside impaired VLDL catabolism, are key features in MASLD pathophysiology.
• Adipokines and inflammatory mediators exacerbate VLDL metabolic disorders in MASLD.

Conclusions:

• VLDL metabolism is central to MASLD development and progression.
• Understanding VLDL-MASLD crosstalk offers new avenues for disease prevention and treatment.
• Targeting VLDL pathways may provide therapeutic benefits for patients with MASLD and related metabolic conditions.